Today: 29 April 2026
Browse Category

NASDAQ:ALT 25 November 2025 - 31 January 2026

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune (ALT) Stock News Today (Dec. 17, 2025): Pemvidutide Catalysts, CEO Transition, and Wall Street Price Targets

Altimmune shares traded near $5.03 early Wednesday after closing at the same level Tuesday, with volatility elevated ahead of a key clinical update expected by year-end. The company’s valuation hinges on pemvidutide’s 48-week IMPACT Phase 2b readout for MASH, due in Q4 2025. Leadership changes and wide analyst price targets have added to market uncertainty. The stock jumped 12% intraday on Dec. 12 before retreating.
17 December 2025
·
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts

Altimmune shares traded around $5.29 at 16:50 UTC on Dec. 12, 2025, down 0.9% after a volatile session with heavy volume. The company is preparing for a CEO transition on Jan. 1, 2026, as investors await key pemvidutide Phase 2b data and an FDA meeting. Analyst targets and options activity are adding to the stock’s swings.
12 December 2025
··
Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune (ALT) Stock: CEO Shake-Up, Imminent MASH Data and 250% Upside Forecasts as of December 9, 2025

Altimmune closed at $5.61 on December 8, 2025, up 7% with heavy trading and high volatility, as short interest reached 30% of float. The company announced CEO Vipin Garg will step down January 1, 2026, with Chairman Jerry Durso taking over ahead of a key MASH trial readout. Analyst targets remain well above current prices despite recent revenue and EPS estimate cuts.
9 December 2025
·
ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Altimmune shares traded near $5.10 on November 25, up about 20% over two weeks after Phase 2b data for lead drug pemvidutide was published in The Lancet and highlighted at AASLD. The stock remains down over 50% from its December 2024 high, with investor sentiment tempered by ongoing shareholder lawsuits and a new $400 million shelf registration.
25 November 2025
··

Stock Market Today

  • Franco-Nevada (TSX:FNV) Valuation Review Amid Share Price Decline
    April 28, 2026, 11:11 PM EDT. Franco-Nevada (TSX:FNV) shares have fallen 3.2% in one day and 6.1% over a week, triggering reassessment of its valuation. Despite a 12.5% drop over 90 days, the stock still shows an 11.2% gain year-to-date and 37.2% total return over one year, revealing fading short-term momentum but solid long-term growth. Shares trade at CA$318.05, below analyst targets near CA$402.66 and a fair value estimate of CA$388.82, indicating an 18.2% undervaluation. Ongoing acquisitions of high-quality gold assets diversify risk and enhance growth potential. However, the 40.3 times price-to-earnings ratio exceeds industry and peer averages, suggesting valuation risk if gold markets weaken or key projects face issues. Investors should weigh growth forecasts against these risks before positioning on Franco-Nevada.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop